Prediction of Flare-ups of Ulcerative Colitis Using Quantitative Immunochemical Fecal Occult Blood Test

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2010 Mar 6

PMID 20205282

Citations 11

Authors

Motoaki Kuriyama

Jun Kato

Koji Takemoto

Sakiko Hiraoka

Hiroyuki Okada

Kazuhide Yamamoto

Affiliations

Soon will be listed here.

Abstract

Aim: To examine the feasibility of predicting the flare-up of ulcerative colitis (UC) before symptoms emerge using the immunochemical fecal occult blood test (I-FOBT).

Methods: We prospectively measured fecal hemoglobin concentrations in 78 UC patients using the I-FOBT every 1 or 2 mo.

Results: During a 20 mo-period, 823 fecal samples from 78 patients were submitted. The median concentration of fecal hemoglobin was 41 ng/mL (range: 0-392 500 ng/mL). There were three types of patients with regard to the correlation between I-FOBT and patient symptoms; the synchronous transition type with symptoms (44 patients), the unrelated type with symptoms (19 patients), and the flare-up predictive type (15 patients). In patients with the flare-up predictive type, the values of I-FOBT were generally low during the study period with stable symptoms. Two to four weeks before the flare-up of symptoms, the I-FOBT values were high. Thus, in these patients, I-FOBT could predict the flare-up before symptoms emerged.

Conclusion: Flare-up could be predicted by I-FOBT in approximately 20% of UC patients. These results warrant periodical I-FOBT in UC patients.

Citing Articles

Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis.

Kim J, Geum M, Son E, Yu Y, Cheon J, Kwon K Gut Liver. 2022; 16(5):736-745.

PMID: 35145044 PMC: 9474485. DOI: 10.5009/gnl210371.

Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction: A Nationwide Population Study.

Moon J, Lee H, Han K, Kim D, Hong S, Soh H J Am Heart Assoc. 2020; 10(1):e017783.

PMID: 33372535 PMC: 7955497. DOI: 10.1161/JAHA.120.017783.

Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis.

Yen H, Chen M, Chang Y, Huang H, Hsu T, Chen Y PeerJ. 2020; 8:e9537.

PMID: 32742803 PMC: 7367046. DOI: 10.7717/peerj.9537.

A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis.

Hanafy A, Monir M, Abdel Malak H, Desoky Aiad M Inflamm Intest Dis. 2018; 3(1):16-24.

PMID: 30505838 PMC: 6266024. DOI: 10.1159/000490795.

Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis.

Uchihara M, Kato J, Tsuda S, Yoshida T, Maekita T, Iguchi M JGH Open. 2018; 1(3):98-104.

PMID: 30483544 PMC: 6207012. DOI: 10.1002/jgh3.12017.

References

Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E . A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007; 146(4):244-55. DOI: 10.7326/0003-4819-146-4-200702200-00003. View

Rozen P, Waked A, Vilkin A, Levi Z, Niv Y . Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit. 2006; 12(6):MT27-32. View

van Rossum L, van Rijn A, Laheij R, van Oijen M, Fockens P, van Krieken H . Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135(1):82-90. DOI: 10.1053/j.gastro.2008.03.040. View

Nakama H, Zhang B, Fattah A . A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer. 2000; 36(5):647-50. DOI: 10.1016/s0959-8049(00)00020-4. View

Nakama H, Fattah A, Zhang B, Uehara Y, Wang C . A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps. Hepatogastroenterology. 2000; 47(32):386-9. View

Greenberg P, Bertario L, Gnauck R, Kronborg O, Hardcastle J, Epstein M . A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol. 2000; 95(5):1331-8. DOI: 10.1111/j.1572-0241.2000.02032.x. View

Saito H, Soma Y, Nakajima M, Koeda J, Kawaguchi H, Kakizaki R . A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Oncol Rep. 2000; 7(4):815-9. DOI: 10.3892/or.7.4.815. View

Tibble J, Sigthorsson G, Bridger S, Fagerhol M, Bjarnason I . Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119(1):15-22. DOI: 10.1053/gast.2000.8523. View

Rozen P, Knaani J, Samuel Z . Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study. Cancer. 2000; 89(1):46-52. View

10.

Nakama H, Zhang B, Zhang X . Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer. 2001; 37(3):398-401. DOI: 10.1016/s0959-8049(00)00387-7. View

11.

Wong W, Lam S, Cheung K, Tong T, Rozen P, Young G . Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer. 2003; 97(10):2420-4. DOI: 10.1002/cncr.11369. View

12.

Young G, St John D, Cole S, Bielecki B, Pizzey C, Sinatra M . Prescreening evaluation of a brush-based faecal immunochemical test for haemoglobin. J Med Screen. 2003; 10(3):123-8. DOI: 10.1177/096914130301000305. View

13.

Wong B, Wong W, Cheung K, Tong T, Rozen P, Young G . A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther. 2003; 18(9):941-6. DOI: 10.1046/j.1365-2036.2003.01783.x. View

14.

Pepys M, Druguet M, Klass H, Dash A, Mirjah D, Petrie A . Immunological studies in inflammatory bowel disease. Ciba Found Symp. 1977; (46):283-304. DOI: 10.1002/9780470720288.ch14. View

15.

Campbell C, Walker-Smith J, Hindocha P, Adinolfi M . Acute phase proteins in chronic inflammatory bowel disease in childhood. J Pediatr Gastroenterol Nutr. 1982; 1(2):193-200. DOI: 10.1097/00005176-198201020-00007. View

16.

Schroeder K, Tremaine W, Ilstrup D . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317(26):1625-9. DOI: 10.1056/NEJM198712243172603. View

17.

Lauritsen K, Laursen L, Bukhave K, Rask-Madsen J . Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut. 1988; 29(10):1316-21. PMC: 1434004. DOI: 10.1136/gut.29.10.1316. View

18.

Mandel J, Bond J, Church T, Snover D, Bradley G, SCHUMAN L . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328(19):1365-71. DOI: 10.1056/NEJM199305133281901. View

19.

St John D, Young G, Alexeyeff M, Deacon M, Cuthbertson A, Macrae F . Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 1993; 104(6):1661-8. DOI: 10.1016/0016-5085(93)90643-q. View

20.

Mazlam M, Hodgson H . Why measure C reactive protein?. Gut. 1994; 35(1):5-7. PMC: 1374622. DOI: 10.1136/gut.35.1.5. View